Apeiron acquires rights for Phase III immunotherapy against high-risk neuroblastoma from CCRI and SIOPEN

APEIRON Biologics AG (Apeiron) today announced the signing of agreements with the Children’s Cancer Research Institute, Vienna (CCRI) and the European Neuroblastoma Research Network (SIOPEN) that grant Apeiron the rights to further develop and commercialize the monoclonal antibody ch14.18 together with these groups. This antibody presently is being investigated by CCRI and SIOPEN in a…

June 22, 2011
No Comments
Apeiron acquires option to license rights to novel oncology compounds from Cleveland Clinic

APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. Press release Presseaussendung

March 15, 2011
No Comments
Apeiron acquires rights for a phase II biologic against neuroblastoma and other cancers from Merck KGaA, Germany

APEIRON Biologics AG (Apeiron) today announced the signing of an agreement that will grant Apeiron the rights to further develop and commercialize the investigational immunocytokine hu14.18-IL2 which has recently shown preliminary activity in a subset of children suffering from neuroblastoma in a Phase II clinical study. Press release Presseaussendung

February 1, 2011
No Comments
Experienced venture capitalist / pharma manager joins Apeiron’s business development team

APEIRON Biologics AG (Apeiron) today announced that Patrick Burgermeister, a seasoned venture capital and pharma manager will play a leading role in the company’s business development activities. He will be engaged in identification and evaluation of new projects, in-licensing/out-licensing activities, portfolio assessment and sourcing new financing opportunities. Press release Presseaussendung

January 10, 2011
No Comments
Apeiron acquires rights to new clinical stage project

APEIRON Biologics AG (Apeiron) today announced that, as part of its effort to broaden its current project portfolio, it has concluded an agreement with Polymun Scientific GmbH (Polymun) granting Apeiron exclusive rights to recombinant human Super Oxide Dismutase (SOD) for treatment of various inflammatory conditions. Press release Presseaussendung  

November 4, 2010
No Comments
Pain alliance with Evotec

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) and APEIRON Biologics AG today announced that they have entered into a collaboration to identify small molecule modulators of DREAM (Downstream Regulatory Element Antagonistic Modulator), a novel target involved in perception of various pain mechanisms. Press release Presseaussendung

October 27, 2010
No Comments
European Biotechnica Award 2010

Apeiron among the three finalists nominated for the EUROPEAN BIOTECHNICA AWARD 2010. Other finalists are listed companies Addex Pharmaceuticals (Switzerland) and Galapagos Genomics (Belgium).

October 4, 2010
No Comments
Biotech-Pharma Partnerships

LISA VR Press Talk: current partnerships between biotech and pharma in Vienna. LISA VR Press Talk

April 30, 2010
No Comments